Isolated cardioprotective solution containing natriuretic peptides (NPs)

A cardioprotective, natriuretic peptide technology, applied in the field of medicine, can solve the problem of no obvious improvement in inflammatory response, and achieve the effects of reducing myocardial damage, improving cardiac function, and preventing damage

Active Publication Date: 2019-09-27
西安国际医学中心有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, HTK liquid has no significant effect on improving the inflammatory response of ischemia-reperfusion injured myocardium

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isolated cardioprotective solution containing natriuretic peptides (NPs)
  • Isolated cardioprotective solution containing natriuretic peptides (NPs)
  • Isolated cardioprotective solution containing natriuretic peptides (NPs)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] An isolated cardioprotective solution 1 containing natriuretic peptide, specifically prepared according to the following steps:

[0033] Step 1, 0.2837g artificially synthesized vascular natriuretic peptide (VNP) was dissolved in 100mL ultrapure water, and the solution concentration obtained was 10 -3 mol / L.

[0034] Step 2. According to the method for preparing HTK liquid, mix 0.8766g sodium chloride, 0.6710g potassium chloride, 0.1842g 2-ketoglutarate-hydrogen-potassium, 0.8132g magnesium chloride hexahydrate, 3.7733g monohydrate-histamine hydrochloride Acid, 27.9289g histidine, 0.4085g tryptophan, 5.4651g mannitol, 0.0022g calcium chloride dihydrate were dissolved in 1000mL ultrapure water to obtain HTK solution.

[0035] Step 3. Take 100 μL of the solution obtained in Step 1 and add it to the HTK solution obtained in Step 2, mix well, and adjust the pH to 7.2-7.4 to obtain the isolated heart protection solution 1 of the present invention.

[0036] In the above iso...

Embodiment 2

[0038] An isolated cardioprotective solution 2 containing natriuretic peptide, specifically prepared according to the following steps:

[0039] Step 1, 0.3466g brain natriuretic peptide (BNP) is dissolved in 100mL ultrapure water, the solution concentration that obtains is 10 -3 mol / L.

[0040] Step 2. According to the method for preparing HTK liquid, mix 0.8766g sodium chloride, 0.6710g potassium chloride, 0.1842g 2-ketoglutarate-hydrogen-potassium, 0.8132g magnesium chloride hexahydrate, 3.7733g monohydrate-histamine hydrochloride Acid, 27.9289g histidine, 0.4085g tryptophan, 5.4651g mannitol, 0.0022g calcium chloride dihydrate were dissolved in 1000mL ultrapure water to obtain HTK solution.

[0041] Step 3. Add 100 μL of the solution obtained in step 1 to the HTK solution obtained in step 2, mix evenly, and adjust the pH to 7.2-7.4 to obtain the isolated heart protection solution 2 of the present invention.

[0042] In the above-mentioned isolated heart protection solutio...

Embodiment 3

[0044] An isolated cardioprotective solution 3 containing natriuretic peptide, specifically prepared according to the following steps:

[0045]Step 1, 0.2360g C-type natriuretic peptide (CNP) was dissolved in 100mL ultrapure water, and the concentration of the obtained solution was 10 - 3 mol / L.

[0046] Step 2. According to the method for preparing HTK liquid, mix 0.8766g sodium chloride, 0.6710g potassium chloride, 0.1842g 2-ketoglutarate-hydrogen-potassium, 0.8132g magnesium chloride hexahydrate, 3.7733g monohydrate-histamine hydrochloride Acid, 27.9289g histidine, 0.4085g tryptophan, 5.4651g mannitol, 0.0022g calcium chloride dihydrate were dissolved in 1000mL ultrapure water to obtain HTK solution.

[0047] Step 3: Take 1 ml of the solution obtained in step 1 and add it to the HTK solution obtained in step 2, mix well, adjust the pH to 7.2-7.4, and obtain the isolated heart protection solution 3 of the present invention.

[0048] In the above isolated cardioprotective ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an isolated cardioprotective solution containing natriuretic peptide (NPs). The isolated cardioprotective solution is a mixture of the NPs and an HTK (Histidine-tryptophane-ketoglutarate) solution. The NPs are any one of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and synthetic vasonatrin peptide (VNP). The concentration of the ANP, BNP, CNP and synthetic VNP in the HTK solution is 10<-8> mol / L to 10<-6> mol / L. The PH of the isolated cardioprotective solution disclosed by the invention is 7.2 to 7.4. The isolated cardioprotective solution containing the NPs can effectively maintain the activity of isolated hearts, improves the cardiac function, and inhibits the myocardial inflammatory reaction.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to an isolated cardioprotective solution containing natriuretic peptide. Background technique [0002] HTK (Histidine-Tryptophane-Ketoglutarate, HTK) heart protection solution, also known as Const protection solution, is a crystalloid imitating intracellular fluid developed by Bretschneider in Germany in 1975. It is currently mainly used for liver, kidney and heart. It can be used for the preservation of transplanted donor organs such as lung and pancreas, and can also be used as a stopper fluid in heart surgery or a lung protection fluid perfused through the pulmonary artery. As a cardioplegia solution, the "balance effect" is a remarkable feature of HTK solution, which can completely perfuse the vascular cavity, and finally achieve the balance of ions, temperature and oxygen metabolism inside and outside the cells. At the same time, the powerful buffer system in HTK ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N1/02
CPCA01N1/021A01N1/0226
Inventor 于军雷升萍陈宝莹严磊王鹏莉
Owner 西安国际医学中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap